Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results … Continued
Kelly Ripa Stars in Public Service Announcements for “QVC Presents Super Saturday LIVE,” Benefitting Ovarian Cancer Research Fund WEST CHESTER, Pa. (June 10, 2014) – Kelly Ripa is shopping to … Continued
Posted by adavis on January 24, 2014 FOR IMMEDIATE RELEASE: January 24, 2014 Washington, DC—In response to a recent speech by Mike Huckabee, in which he stated that women use oral contraceptives because … Continued
Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought … Continued
(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent … Continued
Partnership is a word you’ll hear often from the board members of Caring Together, a Partner Member of the Alliance in eastern New York. The support group was organized in … Continued
The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA … Continued
(May 16, 2014) Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA … Continued
Despite recommendations from the federal government that women at high-risk of developing breast and ovarian cancer be offered genetic counseling and testing at no out of pocket cost, a new … Continued
(May 6, 2014) Tumors use numerous mechanisms to escape detection and killing by the immune system. Results from OCRF-funded research, reported May 4, 2014 in the prestigious journal Nature Medicine, … Continued
This week, the Ovarian Cancer National Alliance submitted comments to the Food and Drug Administration (FDA) about a proposed Guidance for Industry that could have the effect of limiting patient … Continued
(April 30, 2014) A positive pretreatment imaging test more than doubled the likelihood of disease control in platinum-resistant advanced ovarian cancer treated with the folate receptor-targeted drug vintafolide (trade name … Continued
Get email updates about research news, action alerts, and ways to join the fight.
